Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights

Go back to Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights

Voyager Therapeutics (VYGR) PT Lowered to $27 at Baird

November 8, 2018 8:44 AM EST

Baird analyst Brian Skorney lowered the price target on Voyager Therapeutics (NASDAQ: VYGR) to $27.00 (from $31.00) while maintaining a Outperform rating.

The analyst commented, "After initially indicating that the Phase 2 study Voyager is about to start could be fileable, the FDA recently notified Voyager... More